



10-18-04

IPW

Please type a plus sign (+) inside this box →

+

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	10/722,349
		Filing Date	November 24, 2003
		First Named Inventor	LAU, ALLAN S.
		Group Art Unit	1648
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	8	Attorney Docket Number	UCSF-285CON5
ENCLOSURES (check all that apply)			
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement SB08a Form <input type="checkbox"/> Certified Copy of Priority Documents <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Postcard	Remarks
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Signing Attorney/Agent (Reg. No.)	CAROL L. FRANCIS, 36,513 BOZICEVIC, FIELD & FRANCIS, LLP		
Signature			
Date	October 14, 2004		

EXPRESS MAIL LABEL NO. EV 519866436 US

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Express Mail No. EV 519866436 US

**INFORMATION
DISCLOSURE STATEMENT**

Address to:
Mail Stop
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Attorney Docket	UCSF-285CON5
First Named Inventor	LAU, ALLAN S.
Application Number	10/722,349
Confirmation No.	4703
Filing Date	November 24, 2003
Group Art Unit	1648
Examiner Name	Not Yet Assigned
Title:	"METHODS FOR ENHANCING THE PRODUCTION OF VIRAL VACCINES IN CELL CULTURE"

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been viewed and made of record.

All of the references identified herein were disclosed in parent application serial number 09/736,748 filed 12/13/2000 and as such, copies thereof are not included pursuant to the provisions of 37 CFR § 1.98(d).

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. § 102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. UCSF-285CON5 may be charged thereon.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP


Date:

Oct 14, 2004

By:

Carol L. Francis
Carol L. Francis
Registration No. 36,513

BOZICEVIC, FIELD & FRANCIS LLP
1900 University Avenue, Suite 200
East Palo Alto, California 94303
Telephone: (650) 327-3400
Facsimile: (650) 327-3231



Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/722,349		
		Filing Date	November 24, 2003		
		First Named Inventor	LAU, ALLAN S.		
		Art Unit	1648		
		Examiner Name	Not Yet Assigned		
Sheet	1	of	6	Attorney Docket Number	UCSF-285CON5

U.S. PATENT DOCUMENTS						
Examiner Initials'	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)				
		US- RE 33,164		02/13/90	Brown	
		US- 4,579,821		04/01/86	Palmiter et al.	
		US- 5,525,513		06/11/96	Chen	
		US- 5,149,531		09/22/92	Younger	
		US- 5,840,565		11/24/98	Lau	
		US- 6,673,591		01/06/04	Lau	
		US- 6,686,190		02/03/04	Lau	

FOREIGN PATENT DOCUMENTS						
Examiner Initials'	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
		EP 0 414 475	2/1991	Chiron Corp.		
		WO 93 20188	10/1993	Bio Merieux		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/722,349	
			Filing Date	November 24, 2003	
			First Named Inventor	LAU, ALLAN S.	
			Group Art Unit	1648	
			Examiner Name	Not Yet Assigned	
Sheet	2	of	6	Attorney Docket Number	UCSF-285CON5

OTHER ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Aguzzi et al., "Transgenic and knock-out mice: models of neurological disease.", Brain Pathology (1994) 4:3-20	
		Barber et al., "The 58-kilodalton inhibitor of the interferon-induced double-stranded RNA-activated protein kinase is a tetratricopeptide repeat protein with oncogenic properties", Proc. Natl. Acad. Sci. USA, (1994) 91:4278-4282	
		Bowie et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," Science, Vol. 247:1306-1310(1990).	
		Busby et. al., "Isolation of mutant promoters in the Escherichia coli galactose operon using local mutagenesis on cloned DNA fragments", J. Mol. Biol. (1982) 154:197-209	
		Camper et al., "Implementing transgenic and embryonic stem cell technology to study gene expression, cell-cell interactions and gene function", Biology of Reproduction (1995) 52:246-257	
		Candal et al., "Possibilities of vaccine manufacture in human diploid cell strains with a serum replacement factor", Biologicals (1991) 19:213-218	
		Chong et al., "Human p68 kinase exhibits growth suppression in yeast and homology to the translational regulator GCN2", EMBOJ. (1992) 11:1553-1562	
		Clemens, et al. "PKR-A protein kinase regulated by double-stranded RNA", Int. J. Biochem. Cell Biol. (1997) Vol. 29, no. 7, pp. 945-949	
		D'Addario et al., "Coordinate enhancement of cytokine gene expression in human immunodeficiency virus type 1-infected promonocytic cells", J. Virol. (1990)64:6080-6089	
		Deng et al., "Site-directed mutagenesis of virtually any plasmid by eliminating a unique site", Analytical Biochemistry (1992) 200:81-88	
		Der, S.D., et al., "Involvement of the double-stranded RNA-dependent kinase PKR in interferon expression and interferon-mediated antiviral activity", Proc. Natl. Acad. Sci. USA, Vol. 92:8841-8845 (1995).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/722,349		
		Filing Date	November 24, 2003		
		First Named Inventor	LAU, ALLAN S.		
		Group Art Unit	1648		
		Examiner Name	Not Yet Assigned		
Sheet	3	of	6	Attorney Docket Number	UCSF-285CON5

		Du et al., "Mechanisms of transcriptional synergism between distinct virus-inducible enhancer elements", Cell (1993) 74:887-898	
		Feng et al., "Identification of double-stranded RNA-binding domains in the interferon-induced double-stranded RNA-activated p68 kinase.", Proc Natl Acad Sci USA (1992) 89:5447-5451	
		Galabru et al., "Autophosphorylation of the protein kinase dependent on double-stranded RNA", J. Biol. Chem. (1987) 262:15538-15544	
		Green SR et al., "Two RNA-binding motifs in the double-stranded RNA-activated protein kinase, DAI", Genes & Development (1992) 6:2478-2490	
		Gutterman, "Cytokine therapeutics: lessons from interferon alpha", Proc Natl. Acad. Sci. (1994) 91:1198-1205	
		Hassel et al., "A sensitive assay for the IFN-regulated 2-5A synthetase enzyme", J Virol Methods (1994) 50:323-334	
		Henry et al., "Mechanism of interferon action. Translational control and the RNA-dependent protein kinase (PKR): antagonists of PKR enhance the translational activity of mRNAs that include a 161 nucleotide region from reovirus S1 mRNA", J. Biol. Regulators and Homeostatic Agents (1994) 8:1:15-24	
		Hershey et al., "Translational control in mammalian cells", Ann. Rev. Biochem. (1991) 60:717-755	
		Hovanessian, Ara G., "The double stranded RNA-activated protein kinase induced by interferon:dsRNA-PK," J. Interferon Res., Vol. 9(6):641-7 (1989).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/722,349		
		Filing Date	November 24, 2003		
		First Named Inventor	LAU, ALLAN S.		
		Group Art Unit	1648		
		Examiner Name	Not Yet Assigned		
Sheet	4	of	6	Attorney Docket Number	UCSF-285CON5

	Jaramillo, et al., "The interferon system: a review with emphasis on the role of PKR in growth control", Cancer Investigation (1995) (13)3, 327-338.	
	Koromilas, et al. "Malignant transformation by a mutant of the IFN-inducible dsRNA-dependent protein kinase", Science (1992) 257:1685-1689	
	Kumar et al., "Double-stranded RNA-dependent protein kinase activates transcription factor NF-kappa B by phosphorylating I kappa B", Natl. Acad. Sci. USA (1994) 91:6288-6292	
	Lee et al., "The interferon-induced double-stranded RNA-activated human p68 protein kinase inhibits the replication of vaccinia virus", Virol. (1993) 193:1037-1041	
	Lee et al., "The interferon-induced double-stranded RNA-activated human p68 protein kinase potently inhibits protein synthesis in cultured cells", Virology (1993) 192:380-385	
	MacDonald et al., "Development of new cell lines for animal cell biotechnology", Critical Reviews Biotech. (1990) 10:155-178	
	Maran et al., "Blockage of NF-kappa B signaling by selective ablation of an mRNA target by 2-5A antisense chimeras", Science (1994) 265:789-792	
	Marcus et al., "Interferon induction by viruses. XVI. 2-Aminopurine blocks selectively and reversibly an early stage in interferon induction", J. Gen. Virol. (1988) 69:1637-1645	
	Matsuyama et al., "Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development", Cell (1993) 75:83-97	
	McCormack et al., "Mechanism of interferon action motif I of the interferon-induced, RNA-dependent protein kinase (PKR) is sufficient to mediate RNA-binding activity", Virology (1994) 198:92-99	
	McMillan et al., "Mutational analysis of the double-stranded RNA (dsRNA) binding domain of the dsRNA-activated protein kinase, PKR", J. Biol. Chem. (1995) 270:2601-2606	
	Meurs et al., "Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon", Cell (1990) 62:379-390	
	Meurs et al., "Constitutive expression of human double-stranded RNA-activated p68 kinase in murine cells mediates phosphorylation of eukaryotic initiation factor 2 and partial resistance to encephalomyocarditis virus	
	Meurs et al., "Tumor suppressor function of the interferon-induced double-stranded RNA-activated protein kinase", Proc. Natl. Acad. Sci. USA (1993) 90:232-236	
	Ozes et al., "Reversal of interferon-gamma-resistant phenotype by poly(I:C): possible involvement of ISGF2 (IRF1) in interferon-gamma-mediated induction of the IDO gene", J. Interferon Res. (1994) 14:25-32	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/722,349		
		Filing Date	November 24, 2003		
		First Named Inventor	LAU, ALLAN S.		
		Group Art Unit	1648		
		Examiner Name	Not Yet Assigned		
Sheet	5	of	6	Attorney Docket Number	UCSF-285CON5

	Pearson, "Changing issues of quality control: diploid and non-diploid cell lines", Devel. Biol. Standard. (1992) 76:13-17	
	Peetermans, "Production, quality control and characterization of an inactivated hepatitis A vaccine", J. Vaccine (1992) 10 supp 1:S99-S101	
	Pestka et al., "Interferons and their actions", Ann. Rev. Biochem. (1987) 56:727-777	
	Proud C.G., "PKR: a new name and new roles.", Trends Biochem. Sci. (TIBS), (1995) 20:6:241-246	
	Read et al., "Elevated levels of interferon-induced 2'-5' oligoadenylate synthetase in generalized persistent lymphadenopathy and the acquired immunodeficiency syndrome", J. Infect. Dis. (1985) 152:466-472	
	Robertson et al., "Sequence analysis of the haemagglutinin (HA) of influenza A (H1N1) viruses present in clinical material and comparison with the HA of laboratory-derived virus", J. Gen. Virol. (1991) 72:2671-	
	Samuel, Charles E.; Ozato, Keiko, "induction of interferons and interferon-induced genes," Biotherapy (Dordrecht, Neth.), Vol. Date 1994, 8(3/4, Cytokine Yearbook, Vol. 1), 183-187.	
	Sen et al., "The interferon system. A bird's eye view of its biochemistry", J. Biol. Chem. (1992) 267:5017-5020	
	Shevitz et al., in Viral Vaccines Mizrahi, A. ed ppl-35 (1990) Wiley-Liss	
	Tanaka et al., "Cytokine gene regulation: regulatory cis-elements and DNA binding factors involved in the interferon system", Adv. Immunol. (1992) 52:263-281	
	Tannock et al., "Evaluation of chicken kidney and chicken embryo kidney cultures for the large-scale growth of attenuated influenza virus master strain A/Ann/Arbor/6/60-ca", Vaccine (1985) 3:333-339	
	Taylor et al., "Recent progress in interferon research: molecular mechanisms of regulation, action, and virus circumvention", Virus Research (1990) 15:1-26	
	Thomas et al., "IFN-gamma-mediated antimicrobial response. Indoleamine 2,3-dioxygenase-deficient mutant host cells no longer inhibit intracellular Chlamydia spp. or Toxoplasma growth", J Immunol (1993)	
	Visvanathan et al., "Double-stranded RNA activates binding of NF-kappa B to an inducible element in the human beta-interferon promoter", EMBOJ. (1989) 8:1129-1138	
	Williams, "Transcriptional regulation of interferon-stimulated genes", Eur. J. Biochem. (1991) 200:1-11	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/722,349		
		Filing Date	November 24, 2003		
		First Named Inventor	LAU, ALLAN S.		
		Group Art Unit	1648		
		Examiner Name	Not Yet Assigned		
Sheet	6	of	6	Attorney Docket Number	UCSF-285CON5

		Wood et al., "Use of human diploid cells in vaccine production", Biologicals (1990) 18:143-146	
		Zinn et al., "2-Aminopurine selectively inhibits the induction of beta-interferon, c-fos, and c-myc gene expression", Science (1988) 240:210-213	
		ZÜRCHER, et al., "Nuclear localization of mouse Mx1 protein is necessary for inhibition of influenza virus", Journal of Virology, (1992), 66:8:5059-5066	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.